Mesothelioma Most mesotheliomas originate in the pleura and are due to asbestos
exposure. The incidence is decreasing somewhat with asbestos remediation, but mortality …

The sites of targeted therapy are limited and need to be expanded. The FGF‐FGFR
signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a …

Incidence of malignant pleural mesothelioma (MPM) is generally higher in males than
females and is attributed to historical differences in exposures with world-standardised …

Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent
approval of combination immune checkpoint blockade. Here we report the results of the …

The European Respiratory Society (ERS)/European Society of Thoracic Surgeons
(ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for …

Background There is a strong unmet need to improve systemic therapy in mesothelioma.
Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural …

Summary Background Tumour Treating Fields (TTFields) are a regional, antimitotic
treatment for solid tumours, which is based on the delivery of low-intensity alternating …

Background There is a preclinical rationale for inhibiting angiogenesis in mesothelioma. We
aimed to assess the efficacy and safety of the anti-VEGFR-2 antibody ramucirumab …

Introduction Molecular and immunologic breakthroughs are transforming the management of
thoracic cancer, although advances have not been as marked for malignant pleural …

Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options.
Recent advances have led to US Food and Drug Administration approvals and changes in …